| 32.9 1.98 (6.4%) | 02-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.44 | 1-year : | 44.16 |
| Resists | First : | 34.62 | Second : | 37.81 |
| Pivot price | 32.3  |
|||
| Supports | First : | 29.46 | Second : | 24.51 |
| MAs | MA(5) : | 31.27 |
MA(20) : | 32.92 |
| MA(100) : | 32.49 |
MA(250) : | 25.66 |
|
| MACD | MACD : | -1 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 37.7 |
D(3) : | 24.7 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 39.27 | Low : | 13.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IDYA ] has closed below upper band by 36.8%. Bollinger Bands are 2.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.07 - 33.21 | 33.21 - 33.35 |
| Low: | 30.57 - 30.7 | 30.7 - 30.84 |
| Close: | 32.67 - 32.91 | 32.91 - 33.16 |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Wed, 18 Feb 2026
IDYA: Major data readout for darovasertib/crizotinib in uveal melanoma expected by end of March - TradingView
Wed, 18 Feb 2026
Cantor Fitzgerald Maintains Overweight on IDEAYA (IDYA) Feb 18, 2026 - Meyka
Tue, 17 Feb 2026
IDEAYA Biosciences, Inc. SEC 10-K Report - TradingView
Tue, 17 Feb 2026
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q4 Net Loss $0.94 a Share, vs. FactSet Est of $1.05 Loss - marketscreener.com
Tue, 17 Feb 2026
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q4 Revenue $10.9M, vs. FactSet Est of $6.3M - marketscreener.com
Tue, 17 Feb 2026
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 110 (%) |
| Shares Short | 8,710 (K) |
| Shares Short P.Month | 7,220 (K) |
| EPS | -1.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.46 |
| Profit Margin | -74.9 % |
| Operating Margin | 52.1 % |
| Return on Assets (ttm) | -10.8 % |
| Return on Equity (ttm) | -14.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.76 |
| Sales Per Share | 2.45 |
| EBITDA (p.s.) | -2.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -102 (M) |
| Levered Free Cash Flow | -66 (M) |
| PE Ratio | -17.41 |
| PEG Ratio | 0 |
| Price to Book value | 2.64 |
| Price to Sales | 13.42 |
| Price to Cash Flow | -28.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|